Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bc51d4d5e856e3c4a04fbce568ddf6d29> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bc51d4d5e856e3c4a04fbce568ddf6d29 NCIT_P378 "NCI" @default.
- Bc51d4d5e856e3c4a04fbce568ddf6d29 type Axiom @default.
- Bc51d4d5e856e3c4a04fbce568ddf6d29 annotatedProperty IAO_0000115 @default.
- Bc51d4d5e856e3c4a04fbce568ddf6d29 annotatedSource NCIT_C126752 @default.
- Bc51d4d5e856e3c4a04fbce568ddf6d29 annotatedTarget "An orally available inhibitor of human epidermal growth factor receptor (EGFR) exon 20 insertion mutations, with antineoplastic activity. Upon oral administration, mobocertinib, and its active metabolites, specifically and irreversibly binds to and inhibits exon 20 insertion mutations of EGFR. This prevents EGFR-mediated signaling and leads to cell death in tumor cells expressing exon 20 insertion mutations. In addition, mobocertinib may inhibit the activity of other EGFR family members, such as human epidermal growth factor receptor 2 (HER2; ERBB2) and HER4. EGFR, HER-2 and -4 are receptor tyrosine kinases often mutated in numerous tumor cell types. They play key roles in tumor cell proliferation and tumor vascularization." @default.